Cumberland Pharma Reports Phase 2a Safety Data For Ifetroban In Systemic Sclerosis; Shares Slide

Cumberland Pharmaceuticals' stock fell 10.6% after-hours after its Phase 2a ASSIST-SSc trial for ifetroban showed no clear benefit over placebo. The small sample size limited the study's ability to detect meaningful differences. The company plans further studies, but the lack of efficacy data disappointed investors. The broader market was positive, indicating the decline was company-specific. The stock traded at $7.59 after-hours.

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban

Cumberland Pharmaceuticals (CPIX) shares dropped 11% after hours as its Phase 2a ASSIST-SSc trial for oral ifetroban in systemic sclerosis patients showed no clear efficacy. The trial was not designed to evaluate efficacy, and the company plans further studies. Systemic sclerosis affects 100,000 people in the U.S.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis. The 12-month trial with 41 subjects showed ifetroban was generally well-tolerated, with mostly mild adverse events. No efficacy conclusions were drawn due to the small sample size. Cumberland plans to submit findings to the FDA and continue biomarker studies. Ifetroban is also being evaluated in other Phase 2 trials.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis (SSc) patients. The drug was well-tolerated, with a safety profile consistent with prior studies. The trial was not designed to evaluate efficacy. Cumberland plans to submit results to the FDA and conduct further biomarker studies. SSc is a rare autoimmune disease with limited treatment options for cardiac manifestations.

Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results and updated investors after closing a strategic transaction with Apotex Health. Apotex acquired Cumberland’s FDA-approved branded portfolio for $100 million plus $11 million for inventory and transition services. Cumberland declared a $1.50 special dividend. Q2 loss was $3.1 million from continuing operations and $4.1 million net. It reported $63 million assets and $4 million cash at June 30.